Association of CXCR4 mRNA Expression with Clinicopathological Aspects of Invasive Breast Carcinoma

Novan Adi Setyawan, Didik Setyo Heriyanto, Naomi Yoshuantari, Irianiwati Irianiwati





Breast cancer is the most common malignancy in women of which majority histological type is Invasive (Ductal) Carcinoma of No Special Type (NST). The prognosis in breast carcinoma is influenced by many factors such as age, tumor size, degree of histology, and lymph node metastasis. Another factor in the development and metastasis of breast cancer is the chemokine receptor CXCR4 and its ligand, CXCL12. Studies state that the expression of CXCR4 in Breast Invasive Carcinoma associated with clinicopathologic aspects remain unclear. This study aims to determine differences in the level of CXCR4 mRNA expression between clinicopathologic aspects in breast carcinoma..


A total of 50 samples of formalin-fixed paraffin-embedded (FFPE) tissues diagnosed as invasive breast carcinoma (NST) are used in this study. Samples are divided into groups, namely with and without lymph node metastasis, age <45 years and> 45 years, small and large size, low grade and high grade. CXCR4 mRNA expression is quantitatively examined by qRT-PCR. CXCR4 mRNA expression differences between various clinicopathologic aspects were analyzed by One-Way ANOVA


Of the 50 samples, 26 samples (52%) revealed increased expression of CXCR4 mRNA compared to normal tissue. There were no significant differences in mRNA expression of  CXCR4 between various prognostic factors (p> 0.05) such as the status of lymph node metastasis, histologic grading, size, and age. However, the expression of CXCR4 mRNA is increased in breast carcinoma when compared to normal breast tissue. Nonetheless the level of CXCR4 expression alone is not associated to clinicopathologic aspects in invasive breast carcinoma.


CXCR4 mRNA expression did not differ significantly between the various clinicopathological aspects of invasive breast carcinoma.


Keyword: invasive breast carcinoma, mRNA of CXCR4, Clinicopathologic aspects



nvasive breast carcinoma; mRNA of CXCR4; Clinicopathologic aspects

Full Text:



Colditz GA, Chia KS. WHO Classification of Tumours of the Breast: Invasive breast carcinoma: Introduction and general features. Int Agency Res Cancer,Lyon. 2012;4th edition(International Agency for Research on Cancer,Lyon):14–7.

Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: Opportunities for improved survival. J Oncol. 2010;2010.

Bhatia H. Breast Cancer in Asia. Gen Re. 2016;4:2–5.

Mukherjee D, Zhao J. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res [Internet]. 2013;3(1):46–57. Available from:

Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor ( SDF-1 / CXCL12 ) and human tumor pathogenesis. Am J Physiol - Cell Physiol. 2007;292(123):987–95.

Furusato B, Rhim JS. CXCR4 and Cancer. Cancer Drug Discov Dev. 2009;31–46.

Jin F, Brockmeier U, Otterbach F, Metzen E. New Insight into the SDF-1/CXCR4 Axis in a Breast Carcinoma Model: Hypoxia-Induced Endothelial SDF-1 and Tumor Cell CXCR4 Are Required for Tumor Cell Intravasation. Mol Cancer Res [Internet]. 2012;10(8):1021–31. Available from:

Sun Y, Mao X, Fan C, Liu C, Guo A. CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumor Biol. 2014;

Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, et al. Expression of CXCR4 and breast cancer prognosis : a systematic review and meta-analysis. BMC Cancer. 2014;14(49):1–8.

Yu S, Wang X, Liu G, Zhu X, Chen Y. High Level of CXCR4 in Triple-Negative Breast Cancer Specimens Associated with a Poor Clinical Outcome. Acta Med. 2013;Vol.67(Okayama):369–75.

Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A, et al. The Influence of Tumor-Host Interactions in the Ligand / Receptor Axis in Determining Metastatic Risk in Breast Cancer. Am J Pathol. 2009;175(1):66–73.

Darash-yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004;28:1–28.

Ahlfen S Von, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA Quality from FFPE Samples. PLoS One. 2007;2(12):1–7.

Smolinski D Von, Leverkoehne ÆI. Impact of formalin-fixation and paraffin-embedding on the ratio between mRNA copy numbers of differently expressed genes. Histochem Cell Biol. 2005;124:177–88.

Chung J, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, et al. Factors in Tissue Handling and Processing That Impact RNA Obtained From Formalin-fixed , Paraffin-embedded Tissue The Journal of Histochemistry & Cytochemistry. J Histochem Cytochem. 2008;56(11):1033–42.

Abrahamsen HN, Steiniche T, Nexo E, Hamilton-dutoit SJ. Towards Quantitative mRNA Analysis in Paraffin- Embedded Tissues Using Real-Time Reverse Transcriptase-Polymerase Chain Reaction. J Mol Diagnostics. 2003;5(1):34–41.

Macabeo-ong M, Ginzinger DG, Ph D, Dekker N, Mcmillan A, Ph D, et al. Effect of Duration of Fixation on Quantitative Reverse Transcription Polymerase Chain Reaction Analyses. 2002;

Andre F, Xia W, Conforti R, Yongkunwei, Boulet T, Tomasic G, et al. CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. Oncologist. 2009;14:1182–8.

Masuda T, Endo M, Yamamoto Y, Odagiri H, Kadomatsu T, Nakamura T, et al. ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling. Sci Rep. 2015;5:9170.

Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, Engin O, et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis. 2005;22:39–46.

Kishima MO, Eduardo C, Oliveira C De, Banin-hirata BK, Losi-guembarovski R, Oliveira KB De, et al. Immunohistochemical Expression of CXCR4 on Breast Cancer and Its Clinical Significance. Anal Cell Pathol. 2015;2015:1–6.

Wu W, Qian L, Chen X, Ding B. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer. Int J Clin Exp Pathol. 2015;8(10):13217–24.

Popple A, Durrant LG, Spendlove I, Rolland P, Scott I V, Deen S, et al. The chemokine , CXCL12 , is an independent predictor of poor survival in ovarian cancer. Br J Cancer [Internet]. Nature Publishing Group; 2012;106(7):1306–13. Available from:

Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res [Internet]. 2003;5(5):R144-50. Available from:

Ding Y, Li C, Yang Q, Chen C, Cheng Z. The Significance of CXCR4 Expression for the Prediction of Lymph Node Metastasis in Breast Cancer Patients. Chin J Clin Oncol. 2008;5:83–6.

Michal AM, Peck AR. Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Res Treat. 2012;130(3):791–807.

Ramos EAS, Grochoski M, Braun-Prado K, Seniski GG, Cavalli IJ, Ribeiro EMSF, et al. Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer. PLoS One. 2011;6(12):1–9.

Al-souhibani N, Al-ghamdi M, Al-ahmadi W, Khabar KSA. Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. Carcinogenesis. 2014;35(9):1983–92.

Cronin PA, Wang JH, Redmond HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer [Internet]. 2010;10(1):225. Available from:

Xu C, Zhao H, Chen H, Yao Q. CXCR4 in breast cancer : oncogenic role and therapeutic targeting. Dove Press J. 2015;9:4953–64.

Tchafa AM, Ta M, Reginato MJ, Shieh AC. EMT Transition Alters Interstitial Fluid Flow – Induced Signaling in ERBB2 -Positive Breast Cancer Cells. Mol Cancer Res. 2015;13(4):755–64.

Guo S, Xiao DAN, Liu H, Zheng X, Liu LEI, Liu S. Interfering with CXCR4 expression inhibits proliferation , adhesion and migration of breast cancer MDA ‑ MB ‑ 231 cells. Oncol Lett. 2014;8:1557–62.

Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, et al. CXCR4 Protein Epitope Mimetic Antagonist, POL5551, Disrupts Metastasis and Enhances Chemotherapy Effect in Triple Negative Breast Cancer. Mol Cancer Ther. 2016;14(11):2473–85.

Nobutani K, Shimono Y, Mizutani K, Ueda Y. Downregulation of CXCR4 in Metastasized Breast Cancer Cells and Implication in Their Dormancy. PLoS One. 2015;1–17.


  • There are currently no refbacks.